Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17010281 | 0.86 | ERN1 (0.51) | LMNAERN1HPGDTSHRALDH1A1 | |
| SCHEMBL469425 | 0.84 | ALDH1A1 (0.35) | ERN1ALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL1506020 | 0.83 | TSHR (0.33) | LMNAHPGDTSHRALDH1A1KDM4E | |
| SCHEMBL3445997 | 0.80 | ALDH1A1 (0.39) | LMNAERN1HPGDALDH1A1KDM4E | |
| SCHEMBL2679545 | 0.78 | MEN1 (0.36) | LMNAERN1HPGDALDH1A1KDM4E | |
| SCHEMBL17010321 | 0.77 | LMNA (0.39) | LMNAERN1ALDH1A1KDM4ETACR2 | |
| SCHEMBL20504766 | 0.74 | LPL (0.41) | LMNAALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL12811818 | 0.73 | — | — | |
| SCHEMBL453441 | 0.72 | ERN1 (0.68) | LMNAERN1HPGDTSHRALDH1A1 | |
| SCHEMBL462215 | 0.72 | ALDH1A1 (0.32) | LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-108610356-B | Benzoxaborole derivatives for the treatment of bacterial infections | 阿纳科制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3251678-A1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Anacor Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3251678-A1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Anacor Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8703742-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2613788-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008345-B2 | Boron-containing small molecules | BCL6B, BTD, BROX | LMNA 3088/4885ERN1 3162/4885HPGD 4201/4885 |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LMNA 3088/4885ERN1 3162/4885HPGD 4201/4885 |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LMNA 3088/4885ERN1 3162/4885HPGD 4201/4885 |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LMNA 3088/4885ERN1 3162/4885HPGD 4201/4885 |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | LMNA 3088/4885ERN1 3162/4885HPGD 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.